Evidence map›Paper›PMID 36361757›Full record

ArticleInternational journal of molecular sciences2022

The Bottlenecks of Preparing Virus Particles by Size Exclusion for Antibody Generation.

Chi-Hsin Lee, Peng-Nien Huang, Pharaoh Fellow Mwale, Wei-Chu Wang, Sy-Jye Leu, Sung-Nien Tseng, Shin-Ru Shih, Liao-Chun Chiang, Yan-Chiao Mao, Bor-Yu Tsai and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Antiviral Activity of Marine BacteriumInternational journal of molecular sciences · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Chi-Hsin LeePh.D. Program in Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 110301, Taiwan.ORCID 0000-0002-3412-7400
Peng-Nien HuangResearch Center for Emerging Viral Infections, Chang Gung University, Taoyuan 333423, Taiwan.
Pharaoh Fellow MwalePh.D. Program in Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 110301, Taiwan.ORCID 0000-0001-9260-8467
Wei-Chu WangPh.D. Program in Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 110301, Taiwan.ORCID 0000-0002-5452-5537
Sy-Jye LeuGraduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 110301, Taiwan.
Sung-Nien TsengResearch Center for Emerging Viral Infections, Chang Gung University, Taoyuan 333423, Taiwan.
Shin-Ru ShihResearch Center for Emerging Viral Infections, Chang Gung University, Taoyuan 333423, Taiwan.
Liao-Chun ChiangCollege of Life Sciences, National Tsing Hua University, Hsinchu 300040, Taiwan.ORCID 0000-0003-4846-1837
Yan-Chiao MaoDivision of Clinical Toxicology, Department of Emergency Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan.ORCID 0000-0002-8561-0582
Bor-Yu TsaiNavi Bio-Therapeutics Inc., Taipei 10351, Taiwan.
Nhlanhla Benedict DlaminiPh.D. Program in Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 110301, Taiwan.
Tien-Cuong NguyenPh.D. Program in Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 110301, Taiwan.
Chen-Hsin TsaiDepartment of Ophthalmology, Taipei Medical University Hospital, Taipei 110301, Taiwan.
Yi-Yuan YangPh.D. Program in Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 110301, Taiwan.ORCID 0000-0003-2534-8436
Taipei Medical University · TWChang Gung University · TWNational Tsing Hua University · TWTaichung Veterans General Hospital · TWTaipei Medical University Hospital · TW

Funding

Ministry of Health and Welfare, Taiwan MOHW109-TDU-B-212-134014 and MOHW110-TDU-B-212-144014Ministry of Science and Technology, Taiwan MOST 109-2622-B-038-005, MOST 109-2320-B-075A-001, and MOST 110-2320-B-075A-001
6 · The paper itself

Abstract

Enterovirus 71 (EV71) is the major etiological agent contributing to the development of hand-foot-mouth disease (HFMD). There are not any global available vaccines or antibody drugs against EV71 released yet. In this study, we perform the virus immunization in a cost-effective and convenient approach by preparing virus particles from size exclusion and immunization of chicken. Polyclonal yolk-immunoglobulin (IgY) was simply purified from egg yolk and monoclonal single-chain variable fragments (scFv) were selected via phage display technology with two scFv libraries containing 6.0 × 10

Indexed as

EnterovirusEnterovirus A, HumanHand, Foot and Mouth DiseaseSingle-Chain AntibodiesAnimalsChickensEgg YolkVirionSingle-Chain AntibodiesEnterovirus 71 (EV71)hand-foot-mouth disease (HFMD)phage display technologysingle-chain variable fragment (scFv)yolk-immunoglobulin

Identifiers

PMID36361757
PMCPMC9653933
OpenAlexW4307551516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.